ArticleRevista peruana de medicina experimental y salud publica2026
Bacteremia due to Sphingomonas paucimobilis in pediatric and adult patients at a reference hospital in Peru 2020-2024.
Article in Revista peruana de medicina experimental y salud publica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sphingomonas paucimobilis is a ubiquitous bacterium of low virulence that can cause bacteremia, especially in immunocompromised patients. Given the absence of recent reports on this pathogen and its resistance profile in Peru, this series evaluated its clinical and microbiological characteristics in a reference hospital. Six cases confirmed by blood culture between January 2020 and September 2024 were analyzed (4 pe-diatric, 2 adults). All patients presented multiple risk factors or comorbidities, with the majority using a central venous catheter. The mortality observed in the series was 50%. Regarding sensitivity, two isolates showed resistance to third- and fourth-generation cephalosporins and ciprofloxacin, all being sensitive to aminoglycosides and another quinolone such as levofloxacin. S. paucimobilis represents an emerging pathogen, with variable resistance patterns that highlight the need for continuous surveillance and individualized therapeutic management guided by an antibiogram.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.